Please login to the form below

Not currently logged in

Novo Nordisk's Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

Novo Nordisk headquarters 

Novo Nordisk is preparing to launch Xultophy in its first countries in the European Union in the first half of next year after gaining European Commission approval for the diabetes treatment.

Xultophy (formerly known as IDegLira) combines the Danish pharma company's Tresiba (insulin degludec) with its market-leading GLP-1 analogue Victoza (liraglutide) in a once-daily injection.

The new treatment is indicated for adults with type 2 diabetes to help them improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk, said: “We believe that Xultophy represents a new paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe.”

Xultophy's European approval was based on late-stage studies showing it can avoid common side effects of insulin treatment while still lowering blood sugar levels.

The EC's decision follows the Swiss license Novo received for Xultophy earlier this month and its 2012 Japanese approval.

This success is in stark contrast to the product's fortunes in the US where the FDA has yet to approve the Tresiba part of the combination, delaying Novo's launch not only of Tresiba as a monotherapy and Xultophy, but also its combination treatment Ryzodeg (which adds insulin aspart to Tresiba).

Article by
Dominic Tyer

19th September 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...